S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:GHRS

GH Research Stock Forecast, Price & News

$16.30
-0.70 (-4.12 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.80
$17.00
50-Day Range
$16.60
$23.68
52-Week Range
$14.51
$26.91
Volume11,295 shs
Average Volume65,434 shs
Market Capitalization$823.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.


About GH Research

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.

Headlines

GH Research (NASDAQ:GHRS) Trading Down 6.7%
October 18, 2021 |  americanbankingnews.com
GH Research (NASDAQ:GHRS) Shares Gap Down to $16.60
October 13, 2021 |  americanbankingnews.com
GH Research (NASDAQ:GHRS) Shares Down 6.6%
October 11, 2021 |  americanbankingnews.com
GH Research (NASDAQ:GHRS) Shares Gap Up to $20.00
October 8, 2021 |  americanbankingnews.com
GH Research (NASDAQ:GHRS) Shares Gap Down to $21.57
October 4, 2021 |  americanbankingnews.com
GH Research Q2 2021 G&A Expenses $719K
September 25, 2021 |  benzinga.com
GH Research's (GHRS) Buy Rating Reaffirmed at JMP Securities
September 24, 2021 |  americanbankingnews.com
GH Research (NASDAQ:GHRS) Shares Gap Up to $20.56
September 24, 2021 |  americanbankingnews.com
GH Research Plc (GHRS)
August 6, 2021 |  realmoney.thestreet.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GHRS
Employees
8
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$823.49 million
Next Earnings Date
12/23/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

717th out of 1,361 stocks

Pharmaceutical Preparations Industry

342nd out of 668 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












GH Research (NASDAQ:GHRS) Frequently Asked Questions

Is GH Research a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GH Research stock.
View analyst ratings for GH Research
or view top-rated stocks.

What stocks does MarketBeat like better than GH Research?

Wall Street analysts have given GH Research a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but GH Research wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting GH Research?

GH Research saw a decline in short interest in the month of September. As of September 30th, there was short interest totaling 930,900 shares, a decline of 17.6% from the September 15th total of 1,130,000 shares. Based on an average daily trading volume, of 49,700 shares, the days-to-cover ratio is presently 18.7 days. Approximately 3.8% of the shares of the company are short sold.
View GH Research's Short Interest
.

When is GH Research's next earnings date?

GH Research is scheduled to release its next quarterly earnings announcement on Thursday, December 23rd 2021.
View our earnings forecast for GH Research
.

How were GH Research's earnings last quarter?

GH Research PLC (NASDAQ:GHRS) released its quarterly earnings data on Wednesday, September, 22nd. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03.
View GH Research's earnings history
.

What price target have analysts set for GHRS?

4 equities research analysts have issued twelve-month price objectives for GH Research's stock. Their forecasts range from $17.25 to $36.00. On average, they anticipate GH Research's share price to reach $28.56 in the next twelve months. This suggests a possible upside of 75.2% from the stock's current price.
View analysts' price targets for GH Research
or view top-rated stocks among Wall Street analysts.

Who are GH Research's key executives?

GH Research's management team includes the following people:
  • Mr. Theis Terwey M.D., Chief Exec. Officer (Age 45)
  • Ms. Julie Ryan A.C.A., Group Fin. Director (Age 35)
  • Mr. Magnus Halle, Managing Director of Ireland (Age 24)

When did GH Research IPO?

(GHRS) raised $150 million in an IPO on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

What is GH Research's stock symbol?

GH Research trades on the NASDAQ under the ticker symbol "GHRS."

When does GH Research's lock-up period expire?

GH Research's lock-up period expires on Wednesday, December 22nd. GH Research had issued 10,000,000 shares in its initial public offering on June 25th. The total size of the offering was $160,000,000 based on an initial share price of $16.00. After the end of GH Research's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of GH Research?

Shares of GHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GH Research's stock price today?

One share of GHRS stock can currently be purchased for approximately $16.30.

How much money does GH Research make?

GH Research has a market capitalization of $823.49 million.

How many employees does GH Research have?

GH Research employs 8 workers across the globe.

What is GH Research's official website?

The official website for GH Research is www.ghres.com.

How can I contact GH Research?

The company can be reached via phone at 353-1437-8443 or via email at [email protected].


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.